ATTORNEY DOCKET NO.: 14014.0266U3

APPLICATION NO.: 10/700,249

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

1-13 (cancelled)

14. (currently amended) A method of evaluating binding affinity of a test compound to alpha

platelet derived growth factor receptor (\alpha PDGFR) or beta platelet derived growth factor receptor (\beta

PDGFR), said method comprising the steps of:

a) contacting a sample containing said receptor with

(i) an antibody or fragment thereof which specifically binds α PDGFR or β-PDGFR

or a fragment thereof wherein the antibody is selected from the group consisting

of (a) monoclonal antibody and (b) polyclonal antibody; and

(ii) said test compound;

b) measuring the amount of said antibody or fragment thereof bound to said receptor, said

amount being inversely proportional to the amount of test compound which bound to said

receptor.

15. (currently amended) The method of claim 14, wherein the test compound is an agonist of α

PDGFR activity.

16. (currently amended) The method of claim 14, wherein the test compound is an antagonist of α

PDGFR activity.

2

ATTORNEY DOCKET NO.: 14014.0266U3

APPLICATION NO.: 10/700,249

17. (previously presented) The method of claim 14, wherein the test compound is a PDGF-AA

isoform.

18. (previously presented) The method of claim 14, wherein the test compound is a PDGF-AB

isoform.

19. (cancelled)

20. (currently amended) The method of claim 14, wherein the antibody or fragment thereof is

specific for a-protein having the amino acid sequence of a human type a PDGF receptor protein.

21. (cancelled)

22. (new) The method of claim 14, wherein the affinity with which the substance binds to α

PDGFR is compared to the affinity with which the PDGF AA isoform binds to α PDGFR.

23. (new) The method of claim 14, wherein the affinity with which the substance binds to α

PDGFR is compared to the affinity with which the PDGF AB isoform binds to α PDGFR.

24. (new) The method of claim 14, wherein the antibody or fragment thereof is an antibody that

binds to α PDGFR but not to β PDGFR.

25. (new) A method of determining the ability of a substance to bind to Platelet-derived growth

factor receptor alpha (α PDGFR) comprising:

a) providing a sample containing cells expressing $\underline{\alpha}$ PDGFR;

3

ATTORNEY DOCKET NO.: 14014.0266U3 APPLICATION NO.: 10/700,249

- b) exposing said sample of cells expressing $\underline{\alpha}$ PDGFR to a compound suspected of binding to $\underline{\alpha}$ PDGFR; and
- c) measuring the amount of $\underline{\alpha}$ PDGFR activity after exposure of the cell sample.
- 26. (new) The method of claim 25, wherein the compound is an agonist of α PDGFR activity.
- 27. (new) The method of claim 25, wherein the compound is an antagonist of α PDGFR activity.
- 28. (new) The method of claim 25, wherein the ability of the substance to bind to α PDGFR is compared to the ability of the PDGF AA isoform to bind to α PDGFR.
- 29. (new) The method of claim 25, wherein the ability of the substance to bind to α PDGFR is compared to the ability of the PDGF AB isoform to bind to α PDGFR.
- 30. (new) The method of claim 25, wherein the ability of the substance to bind to α PDGFR is compared to the binding ability of an antibody or fragment thereof that binds to α PDGFR but not to β PDGFR.
- 31. (new) The method of claim 25, wherein the cells expressing a PDGFR are a cell line containing a recombinant construct expressing a PDGFR.
- 32. (new) The method of claim 25, wherein the cells expressing α PDGFR are a cell line expressing α PDGFR.